TABLE 1.
Clinical data for patients with suspected VL included in this study
| Group | Patient no. | Mean ± SD duration of illness (days) | Spleen size
(cm)
|
No. of patients in the indicated response
category/total no. tested (%)a
|
||
|---|---|---|---|---|---|---|
| Avg | Range | SAG resp. | SAG resist. | |||
| A | 25 | 19.0 ± 5.3 | 3.7 | 1.5–10.0 | 12/21 (57.0) | 9/21 (43.0) |
| B | 43 | 63.1 ± 19.6 | 6.2 | 3.0–12.0 | 18/37 (48.6) | 19/37 (51.4) |
| C | 53 | 187.5 ± 95.0 | 8.4 | 4.5–15.0 | 27/52 (52.0) | 25/52 (48.0) |
a
Patients who were ELISA positive (n = 121) received a single course of SAG. SAG resp., patients cured by chemotherapy; SAG resist., patients refractory to chemotherapy. Data were based on parasitological and clinical criteria evaluated at the conclusion of treatment.